Screener
Merck & Co. MRK Q2 2026 earnings
Reported August 4, 2026 · Before market open
Revenue$16.6BBeat by $238.1M
EPS-$0.13Beat by $0.14
Revenue estimate$16.4B
EPS estimate-$0.27
“We continued to make substantial progress across our business this quarter, driven by strong execution and growing contributions from new product launches. The FDA approval of LIPFENDRA is an exciting moment for our company and for patients, marking the latest milestone in our nearly 70-year legacy in cardiovascular disease. Together with key regulatory and clinical advances across oncology, HIV and immunology, this achievement reflects the strength of our pipeline and portfolio transformation as we bring forward the next wave of innovation. I am confident in the ongoing execution of our strategy as we deliver for patients and further enhance our long-term growth trajectory.”
Next report
Oct 29, 2026 (In 3 weeks)Revenue estimate$17.3B
EPS estimate$2.19
Valuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Merck & Co. report Q2 2026 earnings?
- Merck & Co. (MRK) reported Q2 2026 earnings on August 4, 2026 before market open.
- What were Merck & Co.'s Q2 2026 revenue and EPS?
- Merck & Co. reported revenue of $16.6B and eps of $-0.13 for Q2 2026.
- Did Merck & Co. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $16.4B by $238.1M. EPS beat the consensus estimate of $-0.27 by $0.14.
- How did Merck & Co.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 5.1% from $15.8B a year earlier.
- Where can I find Merck & Co.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-090045) and the 10-Q periodic report (0000310158-26-000212) directly on SEC EDGAR. The filing index links above go to sec.gov.
